Potassium iodide (KI) is one of the most discussed and most misunderstood radiation emergency preparations. It protects against one specific hazard — radioactive iodine uptake by the thyroid gland — and does nothing for any other radiation exposure or any other organ. Understanding exactly what it does and doesn’t do is essential for making a rational stockpiling decision and knowing when to actually use it.
How KI Protects the Thyroid
The thyroid gland actively concentrates iodine from the bloodstream to produce thyroid hormones. In a nuclear event, radioactive iodine-131 (a major fission product) is released into the environment. It behaves chemically identically to stable (non-radioactive) iodine — the thyroid cannot distinguish between them and concentrates both.
Taking stable KI before or immediately after radioactive iodine exposure saturates the thyroid with non-radioactive iodine, leaving no capacity for the thyroid to absorb I-131. The radioactive iodine passes through the body without being concentrated in the thyroid, dramatically reducing thyroid dose and the subsequent risk of thyroid cancer.
What KI does NOT do:
- Does not protect any other organ
- Does not reduce whole-body radiation dose from external gamma radiation
- Does not protect against any other radioactive isotopes (cesium-137, strontium-90, plutonium)
- Is not a “radiation antidote” or general protection against nuclear fallout
Who Benefits Most from KI
Thyroid cancer risk from radioactive iodine is highest in children under 18 — the younger, the higher the risk. Adults over 40 have the lowest risk, and FDA advises KI for them only when the predicted thyroid exposure is very high. FDA guidance:
| Group | KI priority | Rationale |
|---|---|---|
| Newborns to 1 month | Highest | Very high thyroid absorption rate; highest cancer risk |
| Children 1 month–18 years | High | High thyroid absorption; lifetime cancer risk high |
| Adults 18–40 | Moderate | Some thyroid absorption; meaningful cancer risk |
| Pregnant or breastfeeding women | High | FDA places them in the lowest exposure-threshold group, with children; adult 130 mg dose, and no repeat doses in pregnancy unless no other protection is available |
| Adults over 40 | Low unless high exposure expected | Reduced thyroid absorption; lower cancer risk; higher side effect risk |
FDA Dosing by Age
| Age group | KI dose | Tablet fraction (130 mg tablet) |
|---|---|---|
| Adults ≥18 years | 130 mg | 1 tablet (or 2 × 65 mg tablets) |
| Adolescents 12–18 years | 65 mg; 130 mg if 150 lb (70 kg) or more | ½ × 130 mg tablet, or 1 tablet if 150 lb or more |
| Children over 3–12 years | 65 mg | ½ × 130 mg tablet |
| Pregnant or breastfeeding women | 130 mg | 1 tablet; one dose unless officials direct otherwise |
| Children 1 month–3 years | 32 mg | ¼ × 130 mg tablet crushed in juice/food, or 0.5 mL of 65 mg/mL oral solution |
| Newborns to 1 month | 16 mg | ⅛ × 130 mg tablet or 0.25 mL of oral solution; one dose only, see a doctor if more than one is needed |
One dose protects for about 24 hours, so KI is taken once per day for as long as officials direct. CDC says it is most effective taken within 24 hours before or up to 4 hours after exposure. Pregnant women and newborns should not get repeat doses unless no other protection is available.
Brands, Availability, and Storage
- iOSAT (Anbex): 130 mg and 65 mg tablets. FDA-approved and sold without a prescription.
- Potassium Iodide Oral Solution USP (Mission Pharmacal): Liquid, 65 mg/mL. Easier to dose for infants and young children. ThyroSafe 65 mg tablets are also FDA-approved.
- Shelf life: Go by the expiration date the maker prints on the package. The NRC says KI tablets do not lose effectiveness over time, and FDA has guidance for extending the shelf life of stockpiled tablets.
- State distribution programs: The NRC supplies KI to states that request it for people living within the 10-mile emergency planning zone of a nuclear power plant. States are not required to distribute it; each state decides. Check with your state emergency management or health agency.
When to Take KI: The Decision
KI should be taken only when directed by public health or emergency management officials or a healthcare provider. Do not take KI preemptively for unconfirmed events — the side effects (thyroid suppression, allergic reactions, iodine toxicity at high doses) are real risks, particularly for people with thyroid conditions, iodine allergy, or dermatitis herpetiformis.
The nuclear and radiological emergency preparedness guide — including the full fallout shelter protocol, the 7-10 decay rule, and decontamination procedures — is in nuclear and radiological emergency: shelter, potassium iodide, and fallout survival.
